Cangrelor tetrasodium and Ivosidenib

• Generic Name: cangrelor
• Dosage Forms: n.a.
• Other Brand Names: Kengreal

Used as an adjunct to PCI to reduce the risk of periprocedural MI, repeat coronary revascularization, and stent thrombosis in patients who have not been treated with a P2Y12-receptor antagonist and are not being given a glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitor.

Dual-drug antiplatelet therapy with a P2Y12-receptor antagonist and aspirin is part of the current standard of care in patients with acute coronary syndromes (ACS).

Potential advantages of cangrelor include rapid onset and offset of effect and less interindividual variability in antiplatelet effect (i.e., compared with clopidogrel).

Precise role of cangrelor in the management of ACS remains to be established.

• Generic Name: ivosidenib
• Dosage Forms: n.a.
• Other Brand Names: Tibsovo

Ivosidenib targets a specific gene mutation called IDH1, which can affect your bone marrow. IDH1 mutation prevents young blood cells from developing into healthy adult blood cells, which can result in symptoms of acute myeloid leukemia (AML).

Ivosidenib is used to treat AML in adults with an IDH1 mutation. Your doctor will test you for this gene. Ivosidenib is used when other treatments did not work or have stopped working.

Ivosidenib is also used in adults 75 years and older who have newly-diagnosed AML and cannot use certain chemotherapy treatments because of other health problems.

Ivosidenib may also be used for purposes not listed in this medication guide.